These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6398020)

  • 1. Clinical trial of natural alpha interferon in multiple sclerosis.
    Knobler RL; Panitch HS; Braheny SL; Sipe JC; Rice GP; Huddlestone JR; Francis GS; Hooper CJ; Kamin-Lewis RM; Johnson KP
    Ann N Y Acad Sci; 1984; 436():382-8. PubMed ID: 6398020
    [No Abstract]   [Full Text] [Related]  

  • 2. The placebo effect during a double blind trial of recombinant alpha 2 interferon in multiple sclerosis patients: immunological and clinical findings.
    Hirsch RL; Johnson KP; Camenga DL
    Int J Neurosci; 1988 Apr; 39(3-4):189-96. PubMed ID: 3045033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis.
    Camenga DL; Johnson KP; Alter M; Engelhardt CD; Fishman PS; Greenstein JI; Haley AS; Hirsch RL; Kleiner JE; Kofie VY
    Arch Neurol; 1986 Dec; 43(12):1239-46. PubMed ID: 3535752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of multiple sclerosis with various interferons: the cons.
    Johnson KP
    Neurology; 1988 Jul; 38(7 Suppl 2):62-5. PubMed ID: 3133576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic alpha-interferon therapy of multiple sclerosis.
    Knobler RL; Panitch HS; Braheny SL; Sipe JC; Rice GP; Huddlestone JR; Francis GS; Hooper CK; Kamin-Lewis RM; Johnson KP
    Neurology; 1984 Oct; 34(10):1273-9. PubMed ID: 6384817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrathecal interferon as treatment of multiple sclerosis. A planned multicenter study.
    Jacobs L; O'Malley JA; Freeman A; Reese P
    Arch Neurol; 1983 Oct; 40(11):683-6. PubMed ID: 6354150
    [No Abstract]   [Full Text] [Related]  

  • 7. Systemic interferon therapy for multiple sclerosis. Design of a trial.
    Johnson KP
    Arch Neurol; 1983 Oct; 40(11):681-2. PubMed ID: 6194777
    [No Abstract]   [Full Text] [Related]  

  • 8. Natural killer cell activity in patients with multiple sclerosis given alpha interferon.
    Rice GP; Casali P; Merigan TC; Oldstone MB
    Ann Neurol; 1983 Sep; 14(3):333-8. PubMed ID: 6638954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoregulatory properties of type-I interferons: relevance to multiple sclerosis and the hypereosinophilic syndrome.
    Bartholomé EJ; Roufosse FE
    Acta Clin Belg; 1997; 52(6):350-9. PubMed ID: 9489130
    [No Abstract]   [Full Text] [Related]  

  • 10. Systemic interferon therapy of multiple sclerosis: the pros.
    Knobler RL
    Neurology; 1988 Jul; 38(7 Suppl 2):58-61. PubMed ID: 3133575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Interferon-producing and cytotoxic activity of natural killer cells in multiple sclerosis patients].
    Sorokin AM; Koval'chuk LV; Tunkel' OI; Cheknev SB
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1987; 87(2):211-5. PubMed ID: 2437743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrathecally administered natural human fibroblast interferon reduces exacerbations of multiple sclerosis. Results of a multicenter, double-blind study.
    Jacobs L; Salazar AM; Herndon R; Reese PA; Freeman A; Jozefowicz R; Cuetter A; Husain F; Smith WA; Ekes R
    Arch Neurol; 1987 Jun; 44(6):589-95. PubMed ID: 3579676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-alpha and transfer factor in the treatment of multiple sclerosis: a double-blind, placebo-controlled trial. AUSTIMS Research Group.
    J Neurol Neurosurg Psychiatry; 1989 May; 52(5):566-74. PubMed ID: 2659737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic alpha-interferon in multiple sclerosis. Long-term patient follow-up.
    Panitch HS
    Arch Neurol; 1987 Jan; 44(1):61-3. PubMed ID: 3800723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha interferon clinical trial for multiple sclerosis: design considerations.
    Alter M; Greenstein J; Camenga D; LaRue L
    Neuroepidemiology; 1987; 6(1-2):85-92. PubMed ID: 3306431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation.
    Kastrukoff LF; Oger JJ; Hashimoto SA; Sacks SL; Li DK; Palmer MR; Koopmans RA; Petkau AJ; Berkowitz J; Paty DW
    Neurology; 1990 Mar; 40(3 Pt 1):479-86. PubMed ID: 2179764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infectious Diseases Society of America. Trials of interferon therapy for multiple sclerosis.
    Abb J; Deinhardt F; Zander H; Tenser RB; Rapp F; Goust JM; Fudenberg HH; Vilcek J; Ho M; Merigan TC; Oldstone MB; Jackson GG
    J Infect Dis; 1982 Jul; 146(1):109-15. PubMed ID: 6177805
    [No Abstract]   [Full Text] [Related]  

  • 18. A double-blind trial of hyperbaric oxygen in the treatment of multiple sclerosis.
    Wood J; Stell R; Unsworth I; Lance JW; Skuse N
    Med J Aust; 1985 Sep; 143(6):238-40. PubMed ID: 3897808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis.
    Jacobs L; Salazar AM; Herndon R; Reese PA; Freeman A; Josefowicz R; Cuetter A; Husain F; Smith WA; Ekes R
    Lancet; 1986 Dec 20-27; 2(8521-22):1411-3. PubMed ID: 2878272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intralesional interferon in the treatment of early mycosis fungoides.
    Wolff JM; Zitelli JA; Rabin BS; Smiles KA; Abell E
    J Am Acad Dermatol; 1985 Oct; 13(4):604-12. PubMed ID: 2934438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.